Perspectives on gender and product design

International audienceInteractive technologies have a profound mediating effect on the way we obtain and contribute to knowledge, relate to each other and contribute to society. Often, "gender" is not a factor that is explicitly considered in the design of these technologies. When gender is considered, products are often designed with idealised models of gendered "users" -- designed for men, designed for women, designed for boys, designed for girls, or designed for the "average user" who could be male or female. However, the ways in which gender-bias or gender-neutrality are constructed in the design process and the resulting effect on the interactive artifacts that are produced is not well understood. This workshop will address what HCI is currently bringing, and can bring, to the table in addressing this issue

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Human factors evaluation of the Delco RDS radio receiver and the RDS architecture

This report presents the results of a one year comprehensive human factors analysis on the prototype Delco RDS device supplied by the Minnesota Department of Transportation. RDS devices provide a means of transmitting traffic information to motorist using the existing Traffic Management Center's resources. This study examined the devices and the means of transmitting information using ergonomic and human factors principles. This study expanded upon the functions of these devices and their ability to transmit information, as well as their integration within the automobile. The study was completed by examining the data entry tasks required to transmit messages and the TMC's operations as pertaining to messages and delivery to the end-users. Five tasks were completed with the following findings: Ergonomically, the prototype device requires further refinement to provide a user friendly interface. Linkage analysis and flow charting extracted areas where operations of the device was impeded by design. Simulation and on-road study elicited difficulty in operating the device while maintaining driving proficiency. Highly significant deviations were found between normal driving behavior and driving performance when simultaneously operating the device. This suggests an increase in attentional demand which is placed on the driver operating the device when they should be focused on the task of driving. Finally, assessment of data entry personnel and the TMC operations found several areas for improvement in the CrusaderTM message assembly program interface and message content. Recommendations are provided following each task.Minnesota Department of Transportatio